Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

What is the estimated addressable market size for a fibromyalgia therapy and Tonmya's potential market share? How will the FDA approval of Tonmya affect TONX's stock price in the short term and over the next 12 months? What price is Tonmya expected to launch at and how does that compare to existing fibromyalgia treatments? How will Tonmya impact Tonix’s revenue guidance and earnings per share forecasts? What is the timeline for commercial launch and distribution across the U.S.? How does Tonmya’s efficacy and safety profile compare to existing therapies like Lyrica and Cymbalta? What are the projected sales and profit margins for Tonmya over the next 3‑5 years? How will this approval affect the valuation multiples (P/E, EV/Revenue) relative to peers? What are the key regulatory or post‑approval commitments that could affect future profitability? How will the approval impact analyst consensus estimates and target prices for TONX? What are the risks related to manufacturing capacity, supply chain, and potential product shortages? How might the approval influence insider buying/selling activity and short interest? What are the potential risks of adverse events or litigation that could impact the stock? Does Tonix plan any additional indications or formulations for Tonmya in the future? What is the anticipated impact on the company's debt and liquidity position? Will insurers and Medicare/Medicaid cover Tonmya, and what are the expected reimbursement rates? What is the competitive landscape—are there other pipeline candidates or generics that could erode Tonmya’s market? How will this approval affect the company's cash flow and ability to fund other pipeline programs?